Doribax
(Doripenem)ApprovedSmall molecule
ShionogiDoripenem is an antibiotic used to treat serious bacterial infections, including those in the abdomen, urinary tract, and bloodstream. It works by killing bacteria that cause infections.[2] Doribax is currently approved and in use across 11 indications[4].[1]
Doribax is one of 148 small molecule programs targeting Peritonitis. It is currently in Approved.
11
Indications
23
Total Trials
0
Active Trials
147
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
72 competitors in Septic Shock
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Merrem
BB. Braun Medical Inc.
Approved
Duragesic
CCephalon
Approved
Florinef
Jazz PharmaceuticalsPhase 3
Cyklokapron
JJ Molner
Approved
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapiblyk
AAultman Health Foundation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Urinary Tract Infection6 trials
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210990·403 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210990·403 enrolledShow 3 more trials
Ventilator-Associated Pneumonia3 trials
Complicated Intra-abdominal Infections3 trials
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210938·478 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210938·478 enrolledDoripenem in the Treatment of Complicated Intra-Abdominal Infections
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229060·483 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229060·483 enrolledPneumonia3 trials
Doripenem in the Treatment of Hospital-Acquired Pneumonia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211003·240 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211003·240 enrolledA Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00515034·146 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00515034·146 enrolled7 more indications
Critically Ill1 trial
Single Dose1 trial
Prospective1 trial
Pediatric Patients1 trial
Bacterial Pneumonia1 trial
Adult Subject1 trial
Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects
Completed·—·Phase 1·NCT00925392·40 enrolled
Unspecified1 trial
Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
Completed·—·Phase 4·NCT01401010·12 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 5, 2010
DORIBAX
NDA NDA022106
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Doribax drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Doripenem. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]